Bone marrow cell cycle analysis is a sensitive indicator of changes in bone marrow proliferative activity occurring early in chemically-induced myelotoxicity.
Furthermore, a broad band with molecular mass of 60 kDa was detected from poly (I C) treated liver and bone marrow cell extract by THOC1 specific immunoblot analysis, suggesting that THOC1 protein may not be stable in the absence of THOC5/FMIP.
According to the recent meta-analysis of bone marrow cell therapy for acute and chronic ischemic heart failure, 36 randomized controlled trials and 14 cohort studies, involving, respectively, 996 and 464 treated patients, were performed worldwide; while the control groups consisted of 1,165 subjects, a total of 1,460 patients received autologous cells.
An antibody against the CD45 human specific haematopoietic cell surface marker (hCD45) was used to distinguish and identify engrafted human leukaemic cells from mouse host bone marrow cells by FACS analysis.
One week following a final intravenous immunization, hFIX mice were killed and spleen and bone marrow cells were collected for analysis.
In the mouse micronucleus assay razoxane (200 and 400 mg kg-1 i.p). was cytotoxic to the bone marrow cells (which limited the analysis) but an increase in micronucleated polychromatic erythrocytes was observed in razoxane dosed animals (5-fold compared to control value).
We found that HSCs distribute and expand unevenly among individual bones following transplantation, suggesting that isolation of a limited number of bone marrow cells for serial transplantation and/or analysis can influence experimental outcomes.
For cell cycle analysis, bone marrow cells were incubated with fluorophore-conjugated antibodies as described above, fixed (2% paraformaldehyde, 20 min), stained with Ki67 antibodies (in 0.1% saponin, 1h) and DAPI.
For LSK analysis, bone marrow cells were Fc blocked then stained with mouse lineage antibody cocktail (APC), anti-mouse cKit (FITC) and anti-mouse Sca-1 (PE).
